From: DEA < DEA. Validation@dea.gov < mailto: DEA. Validation@dea.gov >>

Sent: Saturday, January 14, 2023 2:26 AM

To:

Subject: DEA Registration Documents Attached

CAUTION - EXTERNAL EMAIL

Dear Registrant,

You may have already received or will soon receive the following letter via email (include the link for the letter) regarding the signing of the Consolidated Appropriations Act of 2023, eliminating the "DATA-Waiver Program." As a result of this Act implemented and signed December 29, 2022, we are issuing you a new DEA Registration Certificate which will display your current business activity as a Practitioner.

This change will not impact your ability to continue to treat your established patients; it also removes the federal limit on the number of patients you were previously authorized to treat.

Please feel free to review all of the information by logging onto Informational Documents (usdoj.gov)<https://urldefense.com/v3/_https:/www.deadiversion.usdoj.gov/pubs/docs/index.html_;!!LQXXzXo!yfBePBkDY7aK0Pv6phhkJ9yD3kBUzCLF26DI6qd6dKCNzQ6HkCFfTn19iZrmwntAivzhYjeGoJcFpRpLRo5cgQg\$> for more information regarding the elimination of the DATA-Waiver.

Sincerely,

DEA Registration and Program Support

CONFIDENTIALITY NOTICE: This email message, including any attachments, is for the use of the intended recipient(s) only and may contain information that is privileged, confidential, and prohibited from unauthorized disclosure under applicable law. If you are not the intended recipient of this message, any dissemination, distribution, or copying of this message is strictly prohibited. If you received this message in error, please notify the sender by reply email and destroy all copies of the original message and attachments.



U.S. DEPARTMENT OF JUSTICE * DRUG ENFORCEMENT ADMINISTRATION

DIVERSION CONTROL DIVISION

Search

HOME REPORTING **RESOURCES ABOUT US** REGISTRATION



RESOURCES > **Publications & Manuals** > Informational Documents

Informational Documents

Dear Registrants:

On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the "DATA-Waiver Program."

DEA fully supports this significant policy reform. In this moment, when the United States is suffering tens of thousands of opioid-related drug poisoning deaths every year, the DEA's top priority is doing everything in our power to save lives. Medication for opioid use disorder helps those who are fighting to overcome opioid use disorder by sustaining recovery and preventing overdoses. At DEA, our goal is simple: we want medication for opioid use disorder to be readily and safely available to anyone in the country who needs it. The elimination of the X-Waiver will increase access to buprenorphine for those in need.

All DEA registrants should be aware of the following:

- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer needed for any prescription.
- There are no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine.
- The Act does not impact existing state laws or regulations that may be applicable.

Separately, the Act also introduced new training requirements for all prescribers. These requirements will not go into effect until June 21, 2023. The DEA and SAMHSA are actively working to provide further guidance and DEA will follow up with additional information on these requirements shortly. Importantly, these new requirements do not impact the changes related to elimination of the DATA-Waiver Program described above.

Get Email Updates:

Chemical Control Program

CMEA (Combat Meth Epidemic

Controlled Substance Schedules

COVID-19 Information

DEA TOX Toxicology Testing Program

Drug Disposal Information

Drug and Chemical Information

E-commerce Initiatives

Federal Agencies & Related Links

Federal Register Notices

Guidance Document Portal

National Prescription Drug Take Back Day

NFLIS

Publications & Manuals

Ouestions & Answers

Synthetic Drugs

Title 21 Code of Federal Regulations

Sincerely, Title 21 USC Codified CSA

Anne Milgram

Administrator

For information regarding DEA's Diversion Control Division, please visit https://www.DEAdiversion.usdoj.gov. Please contact the Diversion Control Division Policy Section at **ODLP@dea.gov** if you seek additional assistance regarding this or any other matter.

See original signed document

Please visit SAMSHA for additional information:

https://www.samhsa.gov/medication-assisted-treatment/removal-data-waiver-requirement

https://www.samhsa.gov/medication-assisted-treatment









HOME

CONTACT US

A-Z SUBJECT INDEX

PRIVACY NOTICE

WEBSITE ASSISTANCE

REGISTRATION

Applications
Tools
Resources
CMEA Required Training & Self-Certification
Quota Applications
Marihuana Growers Information
Notice of Registration

ABOUT US

Program Description Customer Service Plan DEA Forms & Applications Mailing Addresses Meetings & Events What's New

REPORTING


ARCOS
BCM Online
Chemical Import/Export Declarations
CSOS (Controlled Substances Ordering
System)
Theft/Loss Reporting
Import/Export
Medical Missions
Registrant Record of Controlled
Substances Destroyed
Quotas
Reports Required by 21 CFR
Submit a Tip to DEA
Year-End Reports

RESOURCES

Chemical Control Program
CMEA (Combat Meth Epidemic Act)
Controlled Substance Schedules
COVID-19 Information
DEA TOX Toxicology Testing Program
Drug Disposal Information
Drug and Chemical Information
E-commerce Initiatives
Federal Agencies & Related Links
Federal Register Notices

Guidance Document Portal
National Prescription Drug Take Back
Day
NFLIS
Publications & Manuals
Questions & Answers
Synthetic Drugs
Title 21 Code of Federal Regulations
Title 21 USC Codified CSA





CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE

UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON D.C. 20537

DEA REGISTRA NUMBER	ATION THIS REGISTRATION EXPIRES	FEE PAID
	01-31-2025	\$888
		io .
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
2,2N,3, 3N,4,5	PRACTITIONER	01-17-2022



Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

Form DEA-223 (9/2016)

DEA REGISTRA NUMBER	TION THIS REGISTRATION EXPIRES	FEE PAID		
	01-31-2025	\$888		
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE		
2,2N,3, 3N,4,5	PRACTITIONER	01-17-2022		
AUBURN, ME 042106821				

CONTROLLED SUBSTANCE/REGULATED CHEMICAL REGISTRATION CERTIFICATE UNITED STATES DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WASHINGTON D.C. 20537

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

REPORT CHANGES PROMPTLY

REQUESTING MODIFICATIONS TO YOUR REGISTRATION CERTIFICATE

To request a change to your registered name, address, the drug schedule or the drug codes you handle, please

- 1. visit our web site at deadiversion.usdoj.gov or
- 2. call our customer Service Center at 1-(800) 882-9539 or
- 3. submit your change(s) in writing to:

Drug Enforcement Administration P.O. Box 2639 Springfield, VA 22152-2639

See Title 21 Code of Federal Regulations, Section 1301.51 for complete instructions.

You have been registered to handle the following chemical/drug codes: